secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001937653-24-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q2 2024 net loss $69.3M; cash $395.9M; zanidatamab BLA priority review by Nov 29
--------------------------------------------------------------------------------

- Net loss for H1 2024: $69.3M vs $75.5M loss in H1 2023; revenue $29.3M (down from $42.6M).
- Cash, equivalents and marketable securities $395.9M as of June 30, 2024; runway into 2H 2027.
- FDA granted Priority Review for zanidatamab BLA in 2L HER2+ BTC; PDUFA date Nov 29, 2024.
- Discontinued zanidatamab zovodotin (ZW49) to focus on ZW171 and ZW191 Phase 1 starts in 2H 2024.
- Appointed Leone Patterson as EVP, Chief Business Officer and CFO, effective Sep 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000039/0001937653-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000039/zyme-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001937653-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer